NCT05091099

The Optimal Sequential Therapy After Long Term Denosumab Treatment

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 44 (actual)
• Sponsor: National Taiwan University Hospital · Academic / Other
• Sex: All
• Age: 50 Years – 85 Years
• Healthy volunteers: Not accepted

Summary

This study intends to investigate whether Alendronate and Zoledronate can prevent bone mineral density loss after long-term treatment with Denosumab.

Detailed description

This study intends to use a randomized trial to test whether Alendronate and Zoledronate can avoid the risk of rapid bone loss after the withdrawal of Denosumab.

Conditions

• Osteoporosis

Interventions

Type	Name	Description
DRUG	zoledronate	On time Zoledronate: Zoledronate would be given (one dose for one year) after the completiong of denosumab on time
DRUG	Alendronate and Zoledronate	Alendronate and Zoledronate: Alendronate would be given one month before the the completiong of denosumab and the following 3 months (Total four months). After the completion of Alendronate, Zoledronate would be given (one dose).

Timeline

• Start date: 2022-01-10
• Primary completion: 2025-11-14
• Completion: 2025-11-14
• First posted: 2021-10-25
• Last updated: 2025-11-19

Locations

1 site across 1 country: Taiwan